Cargando…

Effects of Apolipoprotein A-I/High-Density Lipoprotein Cholesterol on Atherosclerotic Vascular Disease: Critical Impact of Atherosclerosis Disease Stage and Disease Milieu?

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Haghikia, Arash, Landmesser, Ulf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060075/ https://www.ncbi.nlm.nih.gov/pubmed/30062206 http://dx.doi.org/10.1016/j.jacbts.2018.03.003

Ejemplares similares

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a)
por: Schwarz, Andrea, et al.
Publicado: (2022)

Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease
por: Besler, Christian, et al.
Publicado: (2012)

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
por: Shapiro, Michael D., et al.
Publicado: (2017)

High-Density Lipoprotein Nanoparticle Imaging in Atherosclerotic Vascular Disease
por: Leeper, Nicholas J., et al.
Publicado: (2017)

Monte Carlo simulations to meet the ESC recommended low-density lipoprotein cholesterol targets
por: Deo, Salil V.
Publicado: (2023)

Relationship between non–high-density lipoprotein cholesterol/apolipoprotein A-I and monocyte/high-density lipoprotein cholesterol ratio and coronary heart disease
por: Li, Ya, et al.
Publicado: (2020)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

Apolipoprotein B is associated with CT-angiographic progression beyond low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in patients with coronary artery disease
por: Shui, Xing, et al.
Publicado: (2023)

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol
por: Sniderman, Allan D., et al.
Publicado: (2016)

Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
por: Doi, Takahito, et al.
Publicado: (2023)

Cholesterol and prevention of atherosclerotic events: limits of a new frontier
por: de Macedo, Luís Eduardo Teixeira, et al.
Publicado: (2016)

High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis
por: Ossoli, Alice, et al.
Publicado: (2016)

Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life
por: Robinson, Jennifer G., et al.
Publicado: (2018)

Reduced Serum Levels of Triglyceride, Very Low Density Lipoprotein Cholesterol and Apolipoprotein B in Parkinson’s Disease Patients
por: Wei, Qiang, et al.
Publicado: (2013)

Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment
por: Yun, Yeo-Min
Publicado: (2023)

Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment
por: Li, Yi-Heng, et al.
Publicado: (2020)

Low-Density Lipoprotein Cholesterol, Structural Atherosclerosis, and Functional Atherosclerosis in Older Japanese
por: Shimizu, Yuji, et al.
Publicado: (2022)

Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations
por: Lütjohann, Dieter, et al.
Publicado: (2023)

The Effects of Apolipoprotein F Deficiency on High Density Lipoprotein Cholesterol Metabolism in Mice
por: Lagor, William R., et al.
Publicado: (2012)

Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases
por: Ivanova, Ekaterina A., et al.
Publicado: (2017)

The Achievement of Non-high-density Lipoprotein Cholesterol Target in Patients with Very High Atherosclerotic Cardiovascular Disease Risk Stratified by Triglyceride Levels Despite Statin-controlled Low-density Lipoprotein Cholesterol
por: Al-Sabti, Hilal, et al.
Publicado: (2022)

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives
por: Adorni, Maria Pia, et al.
Publicado: (2021)

Physiological Bases for the Superiority of Apolipoprotein B Over Low‐Density Lipoprotein Cholesterol and Non–High‐Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk
por: Glavinovic, Tamara, et al.
Publicado: (2022)

Rosiglitazone attenuates atherosclerosis and increases high-density lipoprotein function in atherosclerotic rabbits
por: LI, CHEN, et al.
Publicado: (2015)

Resveratrol protects against diet-induced atherosclerosis by reducing low-density lipoprotein cholesterol and inhibiting inflammation in apolipoprotein E-deficient mice
por: Chang, Geng-Ruei, et al.
Publicado: (2015)

Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low‐Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients
por: Okerson, Ted, et al.
Publicado: (2017)

The Ratio of Triglyceride to High-density Lipoprotein Cholesterol as an Indicator of Risk Stratification for Atherosclerotic Cardiovascular Disease in a Clinical Setting
por: Tani, Shigemasa
Publicado: (2020)

Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe
por: Cheng, Yinchu, et al.
Publicado: (2022)

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
por: Borén, Jan, et al.
Publicado: (2020)

Association of High‐Density Lipoprotein Particles and High‐Density Lipoprotein Apolipoprotein C‐III Content With Cardiovascular Disease Risk According to Kidney Function: The Multi‐Ethnic Study of Atherosclerosis
por: Lamprea‐Montealegre, Julio A., et al.
Publicado: (2019)

Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol
por: Fonseca, Liliana, et al.
Publicado: (2020)

Age‐Related Associations of Low‐Density Lipoprotein Cholesterol and Atherosclerotic Cardiovascular Disease: A Nationwide Population‐Based Cohort Study
por: Jung, Han Na, et al.
Publicado: (2022)

Cumulative non-high-density lipoprotein cholesterol burden and risk of atherosclerotic cardiovascular disease: a prospective community-based study
por: Guan, Xu-Min, et al.
Publicado: (2023)

Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
por: Wilkinson, Michael J., et al.
Publicado: (2023)

Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease
por: Chang, Chiz-Tzung, et al.
Publicado: (2015)

Association between the Non-high-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio and the Risk of Coronary Artery Disease
por: You, Jiayin, et al.
Publicado: (2020)

High-Density Lipoprotein Cholesterol in Age-Related Ocular Diseases
por: Betzler, Bjorn Kaijun, et al.
Publicado: (2020)

Lowering Low-Density Lipoprotein Cholesterol Concentration with Plant Stanol Esters to Reduce the Risk of Atherosclerotic Cardiovascular Disease Events at a Population Level: A Critical Discussion
por: Gylling, Helena, et al.
Publicado: (2020)

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
por: Ference, Brian A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8h65fr1v1sh7c4dqnj86gpefui